NCT04562129 2026-04-01
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
Clinical Trials
13 trialsNCT04387084 2026-03-23
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
University of Southern California
Phase 1 Active not recruiting
NCT03071406 2026-03-11
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT07436390 2026-03-02
MAK
Institute of Oncology Ljubljana
Phase NA Completed
NCT04526730 2026-02-20
Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT07422779 2026-02-20
MAK
Institute of Oncology Ljubljana
Phase NA Recruiting
NCT05358938 2026-02-06
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Active not recruiting
NCT03543969 2026-02-05
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Active not recruiting
NCT05779423 2026-01-06
Cryoablation+Ipilimumab+Nivolumab in Melanoma
Massachusetts General Hospital
Phase 2 Recruiting
NCT07092670 2025-09-05
MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.
Intergruppo Melanoma Italiano
Recruiting
NCT02652455 2025-08-19
Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Completed
NCT06377111 2025-07-14
A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma
University Health Network, Toronto
Phase 1 Recruiting
NCT03012581 2024-02-28
AcSé
UNICANCER
Phase 2 Completed